Rigel Pharmaceuticals (RIGL) is ready for next Episode as it posted an annual sales of 116,880 K

On Friday, Rigel Pharmaceuticals (NASDAQ: RIGL) opened higher 3.40% from the last session, before settling in for the closing price of $20.86. Price fluctuations for RIGL have ranged from $7.48 to $29.82 over the past 52 weeks.

A company in the Healthcare sector has jumped its sales by 24.59% annually for the last half of the decade. Company’s average yearly earnings per share was noted 127.79% at the time writing. With a float of $17.13 million, this company’s outstanding shares have now reached $17.61 million.

In an organization with 147 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.43%, operating margin of 6.03%, and the pretax margin is 2.46%.

Rigel Pharmaceuticals (RIGL) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Rigel Pharmaceuticals is 2.74%, while institutional ownership is 68.89%. The most recent insider transaction that took place on Feb 04 ’25, was worth 42,595. In this transaction EVP & Chief Financial Officer of this company sold 2,036 shares at a rate of $20.92, taking the stock ownership to the 58,969 shares. Before that another transaction happened on Feb 05 ’25, when Company’s EVP & Chief Financial Officer sold 1,734 for $21.93, making the entire transaction worth $38,020. This insider now owns 57,235 shares in total.

Rigel Pharmaceuticals (RIGL) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.2 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 127.79% per share during the next fiscal year.

Rigel Pharmaceuticals (NASDAQ: RIGL) Trading Performance Indicators

Check out the current performance indicators for Rigel Pharmaceuticals (RIGL). In the past quarter, the stock posted a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.41. Likewise, its price to free cash flow for the trailing twelve months is 35.43.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.22, a number that is poised to hit 0.45 in the next quarter and is forecasted to reach 1.12 in one year’s time.

Technical Analysis of Rigel Pharmaceuticals (RIGL)

Let’s dig in a bit further. During the last 5-days, its volume was 0.18 million. That was inferior than the volume of 0.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 23.28%. Additionally, its Average True Range was 1.40.

During the past 100 days, Rigel Pharmaceuticals’s (RIGL) raw stochastic average was set at 49.23%, which indicates a significant increase from 35.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.78% in the past 14 days, which was lower than the 93.10% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $20.03, while its 200-day Moving Average is $14.98. However, in the short run, Rigel Pharmaceuticals’s stock first resistance to watch stands at $22.01. Second resistance stands at $22.46. The third major resistance level sits at $23.16. If the price goes on to break the first support level at $20.87, it is likely to go to the next support level at $20.17. Assuming the price breaks the second support level, the third support level stands at $19.72.

Rigel Pharmaceuticals (NASDAQ: RIGL) Key Stats

There are currently 17,615K shares outstanding in the company with a market cap of 379.85 million. Presently, the company’s annual sales total 116,880 K according to its annual income of -25,090 K. Last quarter, the company’s sales amounted to 55,310 K and its income totaled 12,420 K.